Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]ACI-3847
- Development stage
- Unknown
- Lead developer
- AC Immune
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[18F]ACI-3847 is a next-generation positron emission tomography (PET) radiopharmaceutical developed by AC Immune for the imaging of alpha-synuclein (α-syn) aggregates in the brain. Alpha-synuclein misfolding and accumulation are the primary pathological hallmarks of synucleinopathies, including Parkinson's disease, Multiple System Atrophy (MSA), and Dementia with Lewy Bodies (DLB). This small molecule tracer is engineered to exhibit high affinity and superior selectivity for α-syn fibrils compared to other protein aggregates such as amyloid-beta and tau. By enabling the non-invasive visualization and quantification of α-syn pathology, [18F]ACI-3847 is intended to serve as a vital diagnostic tool for early disease detection, accurate differential diagnosis, and as a longitudinal biomarker to monitor disease progression and the efficacy of disease-modifying therapies in clinical trials.
- Other names
- 18F-ACI-3847Fluorine-18 ACI-3847Fluorine18 ACI-3847Fluorine 18 ACI-3847
02
Targets
SNCA (Alpha-synuclein)
Beyond the preview
Go deeper on [18F]ACI-3847.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [18F]ACI-3847.